EU-OPENSCREEN-DRIVE Small Molecule Screening Call – Proposal Guidelines

Access: This EU-OPENSCREEN-DRIVE small molecule screening call offers funding to enable transnational access to screening facilities supporting a total of 12 projects.

Eligibility:

- Applicants may come from academia or industry (including SMEs).
- Applicants may be working in an institution of a European Member State or Associated country. Up to 2 projects will be open to applicants from outside Europe.
- User access is transnational only. Users are not allowed to access facility(ies) in their home country.
- Principal investigators and members of their research groups from EU-OPENSCREEN-DRIVE beneficiaries are not eligible to apply.
- Applicants commit to have legal and ethical consent regarding their research, their samples and/or their data prior to submitting their application.
- Applicants must agree to comply with the access, IP and dissemination policies described in the statutes of EU-OPENSCREEN ERIC.
- Applicants must agree to comply with EU-OPENSCREEN ERIC/EU-OPENSCREEN-DRIVE privacy policy and terms of submission.
- If you have any doubt or question relating to the eligibility criteria for this call please contact us at help-desk-open-call@eu-openscreen.eu (indicating "EU-OPENSCREEN-DRIVE small molecule screening call" within the subject).

Publication: Open access (gold or green) is required for any publication of access results. EU-OPENSCREEN-DRIVE funding must be clearly acknowledged by: "This project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 823893."

Open access EU-OS chemical biology database (ECBD): Data will be deposited with a flexible privacy model for rapid and safe dissemination and exploitation. Users stay owner of their data. The optional hold period will be 36 months for data publication. There will be high standards of security and traceability of IP (citable indexing of data points (EUOS, DOI or URL) and links to originator labs for primary raw unprocessed data. Data are disseminated according to the FAIR data principles (i.e., Findable, Accessible, Interoperable and Re-usable), allowing communities across academia, SMEs and industry to benefit from EU-OPENSCREEN's activities. Please read more about our EU-OPENSCREEN ERIC database on the link: https://www.eu-openscreen.eu/services/database.html.

Proposal and deadlines: Applicants will submit their proposals via EU-OPENSCREEN-DRIVE website, by connecting to the ARIA online submission platform. The online proposal submission will be open **until September 30, 2019, 20:00 CET**. Applicants will be notified about acceptance or rejection of their proposal within 12 weeks after the closure of the small molecule screening call 1.

ARIA: The ARIA application platform for EU-OPENSCREEN-DRIVE is handled by Instruct-ERIC. Although potential EU-OPENSCREEN-DRIVE users are requested to register with the ARIA system, the application, review, and reporting process will be handled by EU-OPENSCREEN ERIC.

This project has received funding from the European Union´s Horizon 2020 research and innovation programme under the grant agreement No. 823893

Application step by step:

Click on “Begin a new proposal” and follow the instructions.

1. Select Service/Technology

Please select one out of the 3 tracks, which represent the core competencies of EU-OPENSCREEN-DRIVE screening partners, and apply to one of the screening technologies offered by the 12 individual institutions.

2. Confirm Service/Technology Selection

Please confirm your selected facility.

3. Proposal Details (*required fields).

Complete the fields with details of the desired research:

*Project title:** provide a title for your project.

Abstract of the scientific background, project description and main objectives:* provide a concise project overview including target relevance, significance of proposed research and objectives including the expected impact of the research and the potential contribution of a new small molecule for further scientific investigation.

Relevant publications:* please report the relevant literature (up to 5 publications) including literature describing the screening target. For patents, please provide relevant information as additional attachment.

*Please provide a brief description of yours/PI’s CV:** please include in this section a brief overview of your education, professional background, and expertise that supports the proposed research.

Description of scientific work including a detailed description of your previous and current work relating to the proposed project and planned follow-up experiments:* please give also information whether the identified molecules shall be used as tool compounds or to build a starting point for a drug discovery project, and the type of experiments planned after screening for hit validation.

Attachments: please upload attachments here.

*Please specify the target:** Please specify (if possible) the target using the identifiers derived from following databases depending on the target type:

Target TYPE	Where to find ‘IDENTIFIER’
Protein	http://www.uniprot.org
Protein Complex	http://www.uniprot.org
Nucleic Acid	http://www.ncbi.nlm.nih.gov/genbank/
Cell line	http://www.lgcstandards-atcc.org
Tissue	http://bioportal.bioontology.org/ontologies/BTO?p=classes
Organism	http://www.ncbi.nlm.nih.gov/taxonomy
Pathway	http://www.reactome.org OR http://www.geneontology.org
None	-

This project has received funding from the European Union´s Horizon 2020 research and innovation programme under the grant agreement No. 823893

Please indicate biosafety level for the biological material if known/any. *

Please indicate already known molecules reported in the literature that are active against proposed target (including CAS-Number (if available)) if known/ any: * please indicate only few of those that might be useful for validating the assay. The CAS-Number can be derived from a structural search on www.chemspider.com, while known biological activities can be derived from a target name search at www.ebi.ac.uk/chembl/, https://www.probes-drugs.org/compounds, https://probeminer.icr.ac.uk.

Please specify the requested type of hit (agonist/activator, antagonist/inhibitor (or both), allosteric modulator, or other). *

☐ *Please confirm that an established bioassay and associated key bespoke reagents developed at lab-scale are available.**

*Is the assay format compatible with the performance in microtiter plates allowing the quantitative determination of an optical parameter (e.g. absorbance, fluorescence, luminescence) or high content imaging?**

☐ Yes (if yes, please give details) ☐ No (if not, please comment)

*Please provide a detailed description of the screening assay including existing experimental data to prove assay reliability:** please notice that the assay should be described in detail including as much information as available on features such as assay format, readout technology, signal/background ratio, DMSO tolerance, cell lines, signal CV of background population, protein, incubation times, reagent and readout stability and Z'-factor (if available). Please include raw data for verification.

Attachments: please upload attachments here.

Please describe the positive and negative controls which are available and, if applicable, how the positive/negative plate controls are used for calculating the Z'-factor:* please comment.

*Are all other "Prerequisites for applicants" met?** Please comment on the "Prerequisites for applicants" required specifically for each of the screening partner site offers. Specific "Prerequisites for applicants" can be found at the following link under the different partner sites' offers/descriptions: https://drive.eu-openscreen.eu/calls/small-molecule-screening-call.html.

☐ Yes (if yes, please give details) ☐ No (if not, please comment)

Please comment on innovative potential of proposed research.

Please describe gender aspects of the proposed research.

Additional attachments: please upload any additional document relevant for the evaluation of this proposal.

Ethics: does the activity proposed within this call involve research using human cells or tissues (other than from Human Embryos/Foetuses)? *

☐ Yes (if yes, please specify) ☐ No

User statement:

☐ *I agree to be the principal investigator of the submitted project as it is described in the present application**.

This project has received funding from the European Union´s Horizon 2020 research and innovation programme under the grant agreement No. 823893

☐ *I confirm that all relevant authorizations, declarations and accreditation from competent authority(ies) have been obtained in order to process the above mentioned samples and data through EU-OPENSCREEN-DRIVE, for the requested purposes, in full compliance with the applicable EU and National laws.*[*]

☐ *All publications resulting or including data obtained through EU-OPENSCREEN-DRIVE will be published under Open Access.*[*]

☐ *Legal requirements for exporting/importing materials to/from other countries have been met.*[*]

☐ *I agree that EU-OPENSCREEN-DRIVE partners can exploit general information of my project for outreach and reporting purposes (respecting confidentiality of project specifics)*: in case that you do not agree, please give your explanation in the comment section below.

Comments: please add any additional relevant comment and/or information.

4. Your Research Team

Choose which local researchers from your lab will be involved in the project.

Principal Investigator: The principal investigator is a scientist eligible by their institution to apply for grants. Please note that the user profile will be the reviewer's main source of information about the PI, applicant and team.

Note: If you select a Principal Investigator other than yourself they will be contacted by email to verify this submission.

Home Lab Colleagues: in addition to the applicant, please indicate other members of your home institution that will be part of the research project. Only scientists mentioned in this section will be eligible to access facilities (if applicable) if the proposal is approved. Please note that the user profile will be the reviewer's main source of information about the applicant and the team.

Note: Applicants (including PI and home lab colleagues which are mentioned in the proposal) should register for an ARIA account prior to the submission of the proposal or login directly if they are already registered with an ARIA account. Once registered, the applicants are required to follow ARIA instructions. Please note that the user profile will be the reviewer's main source of information about the applicant and the team. Please make sure to provide adequate information for evaluation.

5. Exclude Reviewers

Feel free to exclude reviewers that may have a conflict of interest.

6. Confirm Proposal

Review the information you have entered and submit your proposal for moderation and review.

7. Accept terms and conditions of submission

Accept terms and conditions of the access routes you have selected.

8. Proposal submitted

This project has received funding from the European Union´s Horizon 2020 research and innovation programme under the grant agreement No. 823893

Your proposal has been successfully submitted. You, the applicant, will receive a notification about acceptance or rejection of your proposal within 12 weeks after the closure of small molecule screening call.

This project has received funding from the European Union´s Horizon 2020 research and innovation programme under the grant agreement No. 823893